Biotech | August 06, 2021
Mark W. Womack is the new CEO of Stelis Biopharma
He will be stationed at the company HQ in Bengaluru, India
He will be stationed at the company HQ in Bengaluru, India
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country
In addition to supporting the ongoing development of the first IND-approved product in clinical trials, the proceeds will also be used to expand the 3D printed drug product pipeline
The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022
The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
The facility is expected to be completed in 2024
ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E
Subscribe To Our Newsletter & Stay Updated
